128 results about "Prognosis biomarker" patented technology

The invention belongs to the technical field of medical treatment, and particularly relates to a cancer prognosis marker screening method which comprises the following steps: step 1) acquiring an imaging mass spectrometry flow cytometry analysis data set; 2) performing single cell segmentation on the image in the imaging mass spectrometry flow cytometry analysis data set, and annotating the cell type of the single cell according to the expression intensity of the marker to be screened; 3) identifying an area where the epithelial cells, the immune cells and the fibrotic cells intersect, and obtaining marker expression intensity in the area where the epithelial cells, the immune cells and the fibrotic cells intersect; 4) obtaining an intercellular interaction analysis result based on the cell frequency and the marker expression intensity, and 5) performing regression analysis according to the cell frequency, the marker expression intensity and the intercellular interaction result in different comparison groups, and screening to obtain the prognostic marker.

The invention belongs to the technical field of biological medicine and molecular biology, and relates to application of TRIM38 as a therapeutic target and a prognostic marker of breast cancer. Research accidentally finds that TRIM38 can inhibit proliferation and metastasis of breast cancer, and further research shows that TRIM38 can block autophagy flow of breast cancer cells. Meanwhile, the TRIM38 can have a combined anti-tumor effect with autophagy inhibitors such as hydroxychloroquine and the like. In addition, the research shows that the TRIM38 can also be used as a prognostic marker of a breast cancer patient.

The invention belongs to the field of biological medicine, and relates to application of thymidine-5 '-monophosphate as a colorectal cancer diagnosis and prognosis biomarker. Through comparison of omics data of intestinal flora metabolites of healthy people and colorectal cancer patients and in-vitro and in-vivo level verification, the potential of thymidine-5 '-monophosphate serving as the colorectal cancer diagnostic marker is screened out. Excrement samples needed for detection are easy to obtain, the compliance of patients is improved through non-invasive operation, and the early diagnosis rate of colorectal cancer is expected to be improved.

The present disclosure provides a new therapeutic target and marker, circBCO2, for inhibiting the progression of liver cancer, especially hepatocellular carcinoma. Inhibition of the expression of circBCO2 or destruction of the signal pathway regulated thereby can serve as a potential therapeutic target for inhibiting the progression of liver cancer. Meanwhile, circBCO2 can also serve as a marker, especially a prognostic marker, for HCC.

The invention relates to a nucleic acid aptamer for specifically recognizing a diagnosis and prognosis biomarker CHI3L1 of hepatic fibrosis and application of the nucleic acid aptamer. The nucleic acid aptamer is a nucleic acid aptamer CHI3L1-apt-1, and the nucleotide sequence of the nucleic acid aptamer is shown as SEQ ID NO.1. The invention also provides application of the nucleic acid aptamer in preparation of a reagent, a kit or a sensor for detecting CHI3L1, and the like. The CHI3L1 is used as a diagnosis and prognosis biomarker of hepatic fibrosis, and the aptamer specifically bound with the CHI3L1 is screened out for the first time; the nucleic acid aptamer CHI3L1-apt-1 can be combined with CHI3L1 with high affinity and high specificity, the KD value of the nucleic acid aptamer CHI3L1-apt-1 is 28.7 nM, and the nucleic acid aptamer CHI3L1-apt-1 has application prospects in the aspects of liver fibrosis diagnosis and prognosis. The nucleic acid aptamer CHI3L1-apt-1 can be applied to separation and purification of CHI3L1, preparation of CHI3L1 detection reagents and development of drugs for treating CHI3L1 related diseases, and has wide application prospects and important scientific, social and economic values.

The invention relates to the field of biological medicine, in particular to application of LEPR gene or protein serving as a target in preparation of cholangiocarcinoma treatment products, the fact that LEPR can serve as a cholangiocarcinoma treatment target and a prognostic marker at the same time is found, and research shows that the expression level of LEPR is up-regulated to inhibit proliferation, migration and invasion of CCA cells, so that the cholangiocarcinoma treatment effect is improved, and the cholangiocarcinoma treatment effect is improved. Therefore, the LEPR can be used as an action target of the cholangiocarcinoma treatment medicine and is used for preparing or screening the cholangiocarcinoma treatment medicine.

The invention belongs to the technical field of biological medicine, and particularly discloses application of CCL28 as a biomarker and a therapeutic target in sepsis. The invention particularly relates to application of a CCL28 gene or a detection reagent for the expression quantity of the CCL28 gene in preparation of a kit for diagnosis or prognosis monitoring of sepsis. The expression of the novel immunomodulatory factor CCL28 in a sepsis patient is obviously improved, and the expression level of the novel immunomodulatory factor CCL28 is in obvious negative correlation with poor prognosis of sepsis. Through CLP induction of a sepsis mouse model, the invention finds that the expression level of CCL28 in sepsis mouse blood, abdominal cavity lavage fluid (PLF), liver and kidney is significantly increased. By adopting the recombinant CCL28 for treatment, the bacterial load in the mice with sepsis can be remarkably reduced, and the multi-organ injury of the mice with sepsis can be reduced, so that the survival rate of the mice with sepsis can be remarkably improved. In conclusion, the invention explores a novel immunomodulatory protein CCL28, and the novel immunomodulatory protein CCL28 not only can be used as a diagnosis and prognosis biomarker of sepsis, but also can be used as a novel target spot for treating sepsis.

Disclosed in the present invention is a use of an MP1 gene copy number variation detection reagent in preparation of an NK / T cell lymphoma prognosis kit. The present invention further provides a detection kit comprising the LMP1 gene copy number variation detection reagent, a use thereof, and an NK / T cell lymphoma prognosis method. In the present invention, a copy number variation event of LMP1 gene in an EB virus genome is used as a novel prognosis marker, which has a good prediction value for the overall survival and progression-free survival prognosis of an NK / T cell lymphoma patient, and can realize more accurate and effective prognostic assessment for the NK / T cell lymphoma patient.

The invention belongs to the technical field of biology, and particularly relates to application of Lnc-PLBD1-AS1 and MCEMP1 as prognosis biomarkers of acute ischemic stroke. According to the application disclosed by the invention, it is found that the expression levels of baseline Lnc-PLBD1-AS1 and MCEMP1 of people who are dead within one year after an acute cerebral arterial thrombosis patient is attacked are obviously higher than those of survival patients, and the Lnc-PLBD1-AS1 and MCEMP1 have good prediction efficiency for evaluating the risk of death of the acute cerebral arterial thrombosis patient within one year after the acute cerebral arterial thrombosis patient is attacked by the acute cerebral arterial thrombosis patient is attacked by the acute cerebral arterial thrombosis patient; the expression levels of the baselines Lnc-PLBD1-AS1 and MCEMP1 of people suffering from the adverse function outcome (death or severe disability) of acute cerebral arterial thrombosis patients after attack for 3 months are obviously higher than those of other patients, and the Lnc-PLBD1-AS1 and MCEMP1 have good prediction efficiency for evaluating the risk of the adverse function outcome of the acute cerebral arterial thrombosis patients after attack for 3 months.

The invention relates to application of ADAMTS2 related to gastric cancer. The application comprises an application of the ADAMTS2 inhibitor in preparation of drugs for preventing, relieving and / or treating gastric cancer, an application of a reagent for detecting ADAMTS2 and / or COL3A1 in preparation of a kit or system for predicting gastric cancer prognosis, and a system or a prognosis instrument for predicting gastric cancer prognosis. The metalloproteinase ADAMTS2 is found to be remarkably and highly expressed in gastric cancer tissues and is associated with peritoneal metastasis and tumor dryness. Therefore, ADAMTS2 can be used as a diagnosis and prognosis marker and a treatment target of cervical cancer, and has a huge application prospect.

The application provides a molecular marker for evaluating the prognosis of cervical squamous cell carcinoma and adenocarcinoma and application thereof, and belongs to the technical field of biological detection. Through bioinformatics analysis methods such as multivariate statistical analysis, difference screening, single factor COX regression analysis and multi-factor COX regression analysis, the application obtains an adenine kinase 4 used for evaluating the prognosis marker of cervical squamous cell carcinoma and a brain sponge-shaped deformity 2 protein used for evaluating the prognosis biomarker of cervical adenocarcinoma. Based on the biomarkers of the application, a kit for evaluating cervical squamous cell carcinoma or adenocarcinoma is constructed, which is used for accurately evaluating the prognosis of cervical squamous cell carcinoma or adenocarcinoma.

The invention discloses application of circKIAA1617 serving as an ER < + > breast cancer treatment target and a prognostic marker. According to the invention, circKIAA1617 is found to be used as an ER + breast cancer diagnosis biomarker and a drug treatment target for the first time; experiments prove that in-vitro and in-vivo proliferation of ER + breast cancer cells can be inhibited by interfering expression of circKIAA1617, and proliferation and stemness progress of ER + breast cancer can be promoted by circKIAA1617; the circKIAA1617 can be used for promoting lipophagy of ER < + > breast cancer cells; therefore, the circKIAA1617 plays a role in promoting the cancer in the development of the ER + breast cancer.

The present invention provides methods and composition for diagnosis, prognosis, prevention and / or treatment of cancers such as melanomas. The subject invention provides biomarkers (e.g., galectin-3 (Gal-3)) and methods for assessing the severity of a cancer / tumor and for monitoring the progressing of a cancer / tumor. The compositions according to the subject invention regulate and alter melanoma signaling, growth, and survival. The subject invention also provides molecular mechanisms governing melanoma metastasis to identify candidate diagnostic or prognostic markers and develop novel therapeutic opportunities. Further, the subject invention identifies the tumor-suppressive function of Gal-3 in melanoma cells, emphasizing the negative crosstalk between Gal-3 and NFAT1 and its role in dictating melanoma metastasis.

Methods and uses of immunoconjugates that bind to CD123 (e.g., pivekimab sunirine) in patients with acute myeloid leukemia (AML) are provided. Such immunoconjugates can be used as monotherapies or can be used in combination with BCL-2 inhibitors (e.g., venetoclax), and / or hypomethylating agents (e.g., azacitidine or decitabine) to prepare patients with AML for hematopoietic stem cell transplant and / or to achieve complete remissions in patients with AML, including those with poor prognostic markers.

The invention discloses application of MISP as a breast cancer diagnosis / prognosis marker and a treatment target. The in-depth study on the expression of MISP in breast cancer cells and the influence on malignant biological behaviors such as breast cancer proliferation shows that compared with normal breast epithelial cells, the MISP is highly expressed in the breast cancer cells, the expression of the MISP is highly related to poor clinical prognosis of breast cancer patients, and the proliferation of the breast cancer cells can be inhibited by reducing the expression of the MISP. A new biomarker is provided for diagnosis and prognosis of the breast cancer, a new target spot is provided for treatment of the breast cancer, and important scientific significance is achieved in the aspects of subsequent drug research and development, clinical treatment and the like.

The invention discloses application of FBXO2 in treatment of prostatic cancer, and belongs to the field of prostatic cancer treatment. According to the application of the FBXO2 accelerant in preparation of the medicine for treating the prostatic cancer, specifically, expression of the FBXO2 in prostatic cancer tissue is remarkably reduced, and the high expression level of the FBXO2 is in positive correlation with good prognosis of a patient; fBXO2 overexpression can effectively inhibit prostate cancer cell proliferation and metastasis and induce apoptosis; mechanism research finds that FBXO2 is specifically combined with m6A reading protein YTHDF2 through a carboxyl terminal structural domain of the FBXO2, mediates the m6A reading protein YTHDF2 to generate ubiquitination modification at a K286 site and promotes proteasome dependent degradation of the m6A reading protein YTHDF2. The YTHDF2 is used as a high-expression cancer promoting protein in prostatic cancer, and the degradation of the YTHDF2 can be accelerated by regulating m6A methylation modification of CDKN1C mRNA, so that the tumor progression is driven. A theoretical basis is provided for developing a novel prognostic marker and a treatment strategy.

The application discloses a liver cancer prognosis marker and application thereof, and the liver cancer prognosis marker comprises TXNRD1, HAO1, C1S, OPTN and SNX6. The application provides a group of liver cancer prognosis markers, and a liver cancer patient prognosis prediction model is constructed based on the liver cancer prognosis markers. The liver cancer prognosis markers are obtained through comprehensive gene expression levels, single cell analysis and spatial transcriptome analysis, and the diversity of the data set and the large sample quantity improve the reliability and universality of the liver cancer prognosis markers and the liver cancer patient prognosis prediction model.

The invention provides a colorectum prognosis marker screening method and system, and relates to the technical field of data processing. The method comprises the following steps: collecting colorectum potential prognosis markers to form a colorectum potential prognosis set; collecting and screening crowd data, and performing classification division based on crowd sources to form different classified and screened crowd data; screening and analyzing all colorectal potential prognostic markers in the colorectal potential prognostic set according to diagnosis results for different classified screening population data to form prognostic marker screening data. According to the method, current possible markers are collected and reasonable analysis is carried out by using a proper diagnosis crowd, so that screening of a prognosis marker combination formed by a plurality of markers is realized, and a basis capable of reasonably carrying out colorectal prognosis analysis and judgment is formed.

The present invention belongs to the field of biotechnology and specifically relates to prognostic markers for multiple myeloma and their applications. In one aspect, the present invention provides the use of a reagent for detecting ATF4 in the preparation of a product for diagnosing multiple myeloma or predicting the prognosis of multiple myeloma patients. Preferably, the reagent for detecting ATF4 includes reagents required for detecting ATF4 protein expression levels, RPF content, or translation efficiency. In another aspect, the present invention also provides a system / device for achieving diagnosis and prognosis prediction.

A C1QBP protein can be used in preparation for an oral cancer screening or prognosis marker. A reagent for detecting a C1QBP protein expression level is in preparation for an oral cancer screening or prognosis kit. The C1QBP protein expression level in an oral mucosa tissue of a patient suffering from oral squamous cell carcinoma is found to be remarkably higher than that of a healthy patient. Using a reagent for detecting a C1QBP protein expression level for preparing a screening or prognosis kit of oral squamous cell carcinoma can realize effective screening or prognosis of oral squamous cell carcinoma.

The present invention relates to a method for assessing whether a subject diagnosed with acute myeloid leukemia (AML) will have a negative prognosis or a positive prognosis based on the expression level of SRRM2 on the cell surface of the mother cell of said subject, and the use of the expression level of SRRM2 on the cell surface of the mother cell as a prognostic marker of AML. The invention further relates to the medical use of SRRM2 targeted therapy for the treatment of SRRM2-positive AML patients.

The invention discloses a group of diagnosis, typing and prognostic markers for children Langerhans cell histocytosis, and belongs to the technical field of disease diagnosis. In the invention, an overall metabolic profile of bone marrow aspirates (BMA) of 34 children LCH patients is analyzed, and the patients are divided into three subtypes: single system diseases (SS), multi-system diseases (MS-RO-) without dangerous organ tiredness and multi-system diseases (MS-RO +) with dangerous organ tiredness. The metabonomics characteristics of children diagnosed as LCH are described, the metabolic characteristics of a multi-system LCH (MS-RO +) group with dangerous organs being tired before and after treatment are comprehensively researched, and important metabolic markers for molecular diagnosis, subtype classification, treatment evaluation and prognosis are provided for children patients suffering from LCH, especially high-risk LCH.

The invention belongs to the technical field of biological medicine, and particularly relates to a biliary atresia differential diagnosis and prognosis marker and application thereof. The invention provides the application of the KRT17 expression level as a biliary atresia differential diagnosis and prognostic marker for the first time. KRT17 as a single marker has a relatively high diagnostic value (AUC = 0.880) for BA, the efficiency of KRT17 is superior to all conventional clinical liver function indexes, and when KRT17 is combined with alanine aminotransferase for use, the diagnostic accuracy can be further improved to AUC = 0.904, the KRT17 and CX3CL1 are optimally combined, and the AUC value is as high as 0.938. According to the technology, KRT17 is used as a novel biliary atresia differential diagnosis marker, the defects of an existing differential diagnosis system can be made up to a certain degree, the KRT17 is specifically and highly expressed in biliary atresia liver bile duct epithelial cells, normal control and disease control are not expressed, and therefore more accurate differential diagnosis can be provided clinically.

The invention relates to the technical field of clinical molecular diagnosis and individualized tumor medicine, in particular to a group of children leukemia prognosis biomarkers based on mitochondrial activity and application of the children leukemia prognosis biomarkers. The invention aims to provide a group of children leukemia prognosis biomarkers based on mitochondrial activity, the children leukemia prognosis biomarkers are used for quantifying mitochondrial metabolic activity of children B-ALL patients, and the biomarkers can be used for early prediction of recurrence risk, evaluation of early curative effect and long-term outcome and guidance of application of a BCL-2 inhibitor or an OXPHOS inhibitor. The marker can be used as an accompanying diagnostic marker for predicting the chemotherapy recurrence risk and the reaction of a targeted drug (such as venetoclax); meanwhile, the children leukemia prognosis biomarker provided by the invention can be used as an accompanying diagnostic tool for ALL risk stratification and metabolism targeted therapy (such as a BCL-2 inhibitor) reaction prediction, and the consistency is verified in multiple queues in the specific embodiment of the invention, so that the children leukemia prognosis biomarker is high in clinical generalization performance.

The invention discloses an aptamer magnetic mesoporous fluorescence joint detection method for cyclosporine A and a prognosis biomarker sIL-2R alpha, relates to the technical field of compound detection, and provides a novel fluorescence sensing platform for simultaneously detecting CsA and sIL-2R alpha based on nucleic acid aptamers and magnetic covalent organic frameworks corresponding to two target objects. Wherein the two aptamers both have negative charges, the MCOFs are rich in aldehyde groups and have positive charges, so that the aptamers can be modified on the surfaces of the MCOFs, meanwhile, the COFs material has a regular pore channel, fluorescent signal molecules with a certain size can be embedded in the pore channel, and two target objects are added into a constructed fluorescent sensing platform, so that the detection sensitivity of the COFs material is improved, and the detection sensitivity of the COFs material is improved. According to the present invention, the aptamer can specifically bind to the target object so as to release the fluorescence signal molecule in the pore channel to the supernatant, and the MCOF-2 has good magnetism so as to simply separate the material from the supernatant, such that the two target objects can be simultaneously quantitatively detected through the change of the fluorescence value of the supernatant;

The invention relates to the technical field of biomedicine, in particular to a diagnostic kit based on acute leukemia prognosis and drug sensitivity prediction, which comprises a prediction module I and a prediction module II. The prediction module I is used for predicting the clinical survival rate of a patient and takes one or more of 32 molecules such as CCND3, FERMT3 and PLD4 as prognostic markers; the prediction module II is used for predicting the sensitivity of the body to drugs, and one or more molecules of BMP8B, IGF1R, OTULINL, SLC22A15, CERS1 and PDE4A are used as drug sensitivity markers. By constructing a dual prediction model, the limitation of prediction efficiency of a single biomarker is broken through, functional coupling of survival prognosis and multi-drug sensitivity prediction is realized, and a clinically convertible integrated tool is provided for accurate treatment of AML (acute myeloid leukemia).

The invention discloses a diffuse large B-cell lymphoma prognostic diagnosis marker combination and application thereof. The marker combination disclosed by the invention comprises TCF4 and AURKA. Bioinformatics exploration is utilized, immunohistochemical staining is further utilized to confirm that expression up-regulation of AURKA and TCF4 in clinical DLBCL cases is related to poor prognosis of patients, and the two molecules have a co-expression relationship with c-MYC. Researches prove that AURKA and TCF4 are markers for poor prognosis of DLBCL patients, TCF4 is a potential target spot in DLBCL treatment, a new prognostic marker is provided for DLBCL, and a theoretical basis is provided for further exploration of a treatment strategy of combined use of the AURKA and an AURKA inhibitor.

A method of using CST1 and GPX4 as a gastric cancer metastasis marker or prognostic marker. The method detects the protein expression of CST1 and GPX4, draws an ROC curve using SPSS software, obtains the sensitivity and specificity of the diagnosis, and calculates the area under the curve AUC value. Finally, the gastric cancer samples are classified according to the AUC value, sensitivity and specificity, and applied to the diagnosis of gastric cancer metastasis. CST1 and GPX4 are used as markers for joint detection of gastric cancer, and the detection has strong specificity and high sensitivity, which can effectively avoid false positive or false negative results that are prone to occur when CST1 or GPX4 is used alone as a diagnostic marker, and provide reliable information for the early diagnosis of gastric cancer metastasis. The method draws a survival curve through follow-up and survival analysis, determines that patients with double positive results of CST1 and GPX4 have a worse prognosis, and provides a biomarker for predicting the prognosis of gastric cancer. The present invention provides a combined biomarker for early diagnosis and prognosis of gastric cancer metastasis with strong specificity and high sensitivity, and its application.

The present invention discloses the application of RGS14 in the preparation of a kit for the auxiliary diagnosis or prognosis of liver cancer and the application of an RGS14 expression inhibitor in the preparation of a drug for treating liver cancer. The present invention discovers for the first time that the expression of RGS14 in liver cancer is significantly increased compared with that in adjacent tissues, and the high expression of RGS14 is not conducive to the overall survival of liver cancer patients; and when RGS14 is knocked down, the colony formation and migration of liver cancer cells are significantly inhibited. The high expression of RGS14 is closely related to the poor prognosis of liver cancer patients, suggesting that RGS14 can be used as a prognostic marker for liver cancer, providing effective information for the prognostic evaluation and efficacy monitoring of liver cancer. The present invention also provides an RGS14 expression inhibitor siRNA, which has good interference effect when used for inhibiting the expression of RGS14 and has potential for clinical application.

The invention discloses an application of TCF7L2 (T cell factor 7L2) in treatment of glioblastoma. The research shows that the transcription factor TCF7L2 has an important tumor inhibition effect in glioblastoma cells (GBM), and the deletion of the transcription factor TCF7L2 can obviously accelerate the growth and malignant progression of tumor cells, so that the response capability of the GBM cells to exogenous neural signals is enhanced, and the tumor development is further promoted. In mechanism, the TCF7L2 regulates and controls the expression of various neurotransmitter receptors, and inhibitors applying the receptors can effectively reverse tumor promoting phenotypes caused by deletion of the TCF7L2, so that the TCF7L2 plays a key role in inhibiting GBM nerve dependence progression by maintaining the steady state of neural signal related receptors. The invention provides a new diagnostic and prognostic marker and a new therapeutic target for treatment of GBM, and provides a new thought and a new strategy for treatment of GBM.